Also known as Christmas factor and plasma thromboplastin component.
Three researchers honoured for creating a bispecific antibody that mimics Factor VIII, enabling subcutaneous dosing and bleed prevention irrespective of inhibitors.
Interim FRONTIER4 data show consistent safety and efficacy of denecimig across weekly, biweekly and monthly dosing, with low injection-site reactions and high zero-bleed rates.
